Hypopharyngeal and upper esophageal ulceration after cervical spine radiotherapy concurrent with crizotinib.

about

Hypopharyngeal and upper esophageal ulceration after cervical spine radiotherapy concurrent with crizotinib.

Item

http://www.wikidata.org/entity/Q39263651

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Hypopharyngeal and upper esoph ...... py concurrent with crizotinib.

@en

Hypopharyngeal and upper esoph ...... py concurrent with crizotinib.

@nl

type

Item

label

Hypopharyngeal and upper esoph ...... py concurrent with crizotinib.

@en

Hypopharyngeal and upper esoph ...... py concurrent with crizotinib.

@nl

prefLabel

Hypopharyngeal and upper esoph ...... py concurrent with crizotinib.

@en

Hypopharyngeal and upper esoph ...... py concurrent with crizotinib.

@nl

P1476

Hypopharyngeal and upper esoph ...... py concurrent with crizotinib.

@en

P2093

Gabriele Beckmann

http://www.w3.org/2001/XMLSchema#string

Marcus H Zimmermann

http://www.w3.org/2001/XMLSchema#string

Michael Flentje

http://www.w3.org/2001/XMLSchema#string

Pius Jung

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment.

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.

Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma.

ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

P2888

s00066-017-1135-8

P304

589-592

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00066-017-1135-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

193

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28444429

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

crizotinib